Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To evaluate the toxicity/safety profile of docetaxel/cisplatin induction therapy
followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by
consolidation docetaxel/cisplatin in patients with locally advanced unresectable NSCLC
(stage IIIA- multiple cN2 or IIIB).
Secondary Objective:
- To estimate efficacy parameters in overall response rate, progression free survival and
1 year survival for each of the two above mentioned arms.